Home/Merus/Cecile Geuijen, Ph.D.

CG

Cecile Geuijen, Ph.D.

SVP & Chief Scientific Officer

Therapeutic Areas

Merus Pipeline

Drug	Indication	Phase
petosemtamab (MCLA-158)	Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+)	Phase 3

Leadership Team at Merus

Jan G.J. van de Winkel, Ph.D.

Executive Director and Chief Executive Officer

John de Kruif, Ph.D.

EVP & Chief Technology Officer

Ernesto Wasserman, M.D.

SVP of Clinical Development

View full Merus profile